Randomized, open label, multicentre phase II trial followed by phase III comparing overall survival after having selected the best experimental arm.

Inclusion Criteria:

• Histologically proven adenocarcinoma of the colon or rectum without previous resection, or clinically asymptomatic (with or without stent)
• Hepatic unresectable metastases R0: due to close vascular contact, or due to liver remaining mass less than 25 to 30 % of functional liver.
• Not optimally resectable metastases
• Extra-hepatic disease will be accepted in case of: asymptomatic primary tumour or tumor requiring no urgent surgery (in less than 3 months); three of less than three lung metastases (thoracic scan diameter less than 2 cm) and potentially respectable.
• Synchronous and metachronous hepatic metastases
• WHO performance status 0-1
• Adjuvant chemotherapy allowed, except oxaliplatin and irinotecan based combination.
• No prior treatment of the liver metastases, whatever.
• Life expectancy equal or more than 3 months

Exclusion Criteria:

-